DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

HOLO MicroCloud Hologram Inc.

MicroCloud Hologram Inc. (HOLO) is a Chinese technology company specializing in holographic LiDAR technology, autonomous driving ADAS systems, and holographic digital twin solutions. The company represents a **recovery play** from a post-reverse-split penny stock to a **profitable, cash-rich operation** with significant exposure to the autonomous vehicle and advanced driver assistance systems (ADAS) market

RVPH Reviva Pharmaceuticals

RVPH

FDA Pre-NDA Meeting (Schizophrenia)
TIMEFRAME: Q4 2025 (IMMINENT)
The Event: Reviva has a scheduled meeting with the FDA in Q4 2025 to discuss submitting a New Drug Application (NDA) for Brilaroxazine based solely on existing data (RECOVER-1 Phase 3 + OLE Long-term data).

Weekly Market Analysis & Trading Outlook

Weekly Market

The week of November 24-29 closed with continued volatility as investors digested stretched AI valuations, mixed macro signals, and elevated geopolitical tensions. Major indexes ended modestly lower: S&P 500 [finance:S&P 500] -1.9%, Nasdaq [finance:Nasdaq Composite] -2.7%, Dow [finance:Dow Jones Industrial Average] -1.9%.

CODX Co-Diagnostics

Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company specializing in the development, manufacturing, and commercialization of rapid PCR diagnostic tests. Core focus: affordable, rapid tuberculosis (TB) detection tests for global markets (MENA, Africa, Asia). Company historically revenue-focused but currently in severe financial distress with strategic pivots toward AI and international partnerships.

LXRX Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products using its proprietary gene science approach. The company operates in two segments: Product (INPEFA® commercialization) and Licensing (Novo Nordisk partnership for LX9851 obesity program).

ONMD OneMedNet Corporation

OneMedNet Corporation (NASDAQ: ONMD) is a healthcare technology company specializing in curating and providing regulatory-grade Real-World Data (RWD) through its proprietary iRWD™ platform. The company connects life sciences organizations, medical device companies, and AI researchers with de-identified medical imaging, electronic health records, and clinical data from over 2,130 healthcare provider sites spanning 47+ million unique patient lives and 186+ million clinical exams.

MBOT Microbot Medical Inc.

Microbot Medical is a commercial-stage medical device company specializing in endovascular robotic systems. The company achieved a transformational milestone in September 2025 with FDA 510(k) clearance for its flagship LIBERTY® Endovascular Robotic System - the world's first FDA-cleared single-use, remotely operated robotic platform for peripheral endovascular procedures.

VRCA Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals [finance:Verrica Pharmaceuticals Inc.] (NASDAQ: VRCA) is a commercial-stage dermatology biopharmaceutical company focused on developing and commercializing innovative medical aesthetic solutions for skin conditions including molluscum contagiosum, basal cell carcinoma, and aesthetic dermatology indications. The company operates through a partnership model, leveraging strategic alliances with larger pharmaceutical companies (Torii Pharmaceutical [finance:Torii Pharmaceutical Co., Ltd.]) for commercialization and geographic expansion.

ACRS Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage dermatology-focused biopharmaceutical company developing innovative immunological therapies for inflammatory and immune-mediated skin diseases. The company transitioned from a commercial-stage company with FDA-approved products to a clinical-stage organization, strategically acquiring promising pipeline assets to build a competitive portfolio in atopic dermatitis and related indications.

AMRN Amarin Corp

? Amarin Corporation (AMRN) – Company History & Analysis ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a company analysis and financial summary compiled from publicly available sources (SEC filings, press releases, clinical publications). It is NOT investment advice,…

AVXL Anavex Life Sciences

What happened: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed Anavex of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its oral explanation on November 11, 2025.

NRXP

NRXP

NRx Pharmaceuticals (NRXP) | Investment Research Report ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT…

CUE Biopharma

Cue Biopharma (CUE) | Investment Research Report ?? English Version ? Cue Biopharma (CUE) Investment Research Report — Platform Play: Immuno-STAT T-Cell Modulators Update: November 26, 2025 ⚠️ GOING CONCERN WARNING ? STRATEGIC PIVOT TO AUTOIMMUNE NASDAQ: CUE | Price:…

KALA Bio Caution risk 100%

KALA Bio was a clinical-stage biotech developing KPI-012, a mesenchymal stem cell secretome (MSC-S) therapy for Persistent Corneal Epithelial Defect (PCED), an orphan eye disease with ~100,000 US patients and no FDA-approved treatments.

CAPR Capricor

Capricor Therapeutics [finance:Capricor Therapeutics, Inc.] is a clinical‑stage biotech focused on cell and exosome‑based therapeutics for rare diseases, with lead asset Deramiocel (CAP‑1002) targeting cardiomyopathy in Duchenne muscular dystrophy